New strategies in non-small cell lung cancer: Improving outcomes in chemoradiotherapy for locally advanced disease

Clinical Cancer Research

Volumn 17, Issue 13, 2011, Pages 4192-4199

  Rengan, Ramesh ^a   Maity, Amit M ^a   Stevenson, James P ^b   Hahn, Stephen M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 2 MORPHOLINO 8 PHENYLCHROMONE; 2 NITROIMIDAZOLE; 3' FLUOROTHYMIDINE F 18; 4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GEFITINIB; GEMCITABINE; LIFICIGUAT; MITOMYCIN; NAVELBINE; NELFINAVIR; NVP BEX 235; PACLITAXEL; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; SOMATOMEDIN BINDING PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINDESINE;

ACTIVE BREATHING CONTROL; ADVANCED CANCER; BREATHING; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FUNCTIONAL ASSESSMENT; GUIDED IMAGERY; HEALTH CARE QUALITY; HUMAN; HYPOXIA; INSPIRATORY CAPACITY; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN TARGETING; PROTON THERAPY; RADIOSENSITIZATION; REVIEW; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT PLANNING; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 79960329784     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2760     Document Type: Review

References (85)

1. Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-5. (Pubitemid 26302034)
2. Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995;87:198-205.
3. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-9. (Pubitemid 29415225)
4. Curran W Jr., Scott C, Langer C, Komaki R, Lee JS, Hauser S, et al. Phase III comparison of sequential vs. concurrent chemoradiation for patients (pts) with unresected stage III non-small cell lung cancer (NSCLC): Initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 2000;19:1891.
5. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500-7. (Pubitemid 36706537)
6. Verhagen AF, Bootsma GP, Tjan-Heijnen VC, van der Wilt GJ, Cox AL, Brouwer MH, et al. FDG-PET in staging lung cancer: how does it change the algorithm? Lung Cancer 2004;44:175-81.
7. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, De Leyn PR, De Wever W, Verbeken EK, et al. The impact of (18)F-fluoro-2-deoxy- D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 2000;55:317-24.
8. Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Douillard JY, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma. Lung Cancer 1994;10[Suppl 1]:S239-44.
9. Saunders M, Dische S, Barrett A, Harvey A, Gibson D, Parmar MCHART Steering Committee. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. Lancet 1997;350:161-5.
10. Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Palmar M. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol 1999;52:137-48.
11. Schaake-Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-30.
12. Verheij M, Vens C, van Triest B. Novel therapeutics in combination with radiotherapy to improve cancer treatment: rationale, mechanisms of action and clinical perspective. Drug Resist Updat 2010;13: 29-43.
13. Nanjundan M, Byers LA, Carey MS, Siwak DR, Raso MG, Diao L, et al. Proteomic profiling identifies pathways dysregulated in nonsmall cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. J Thorac Oncol 2010; 5:1894-904.
14. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in nonsmall- cell lung cancer. Nature 2007;448:561-6. (Pubitemid 47206930)
15. Sasaki T, Rodig SJ, Chirieac LR, Jänne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010;46: 1773-80.
16. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12:175-80.
17. Neal JW, Sequist LV. Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. Curr Treat Options Oncol 2010;11: 36-44.
18. Andreu-Martínez FJ, Martínez-Mateu JM. Hypoxia and anaemia in patients with cancer of the uterine cervix. Clin Transl Oncol 2005;7:323-31.
19. Isa AY, Ward TH, West CM, Slevin NJ, Homer JJ. Hypoxia in head and neck cancer. Br J Radiol 2006;79:791-8. (Pubitemid 44613678)
20. Le QT, Denko NC, Giaccia AJ. Hypoxic gene expression and metastasis. Cancer Metastasis Rev 2004;23:293-310. (Pubitemid 38881813)
21. Lundgren K, Holm C, Landberg G. Hypoxia and breast cancer: prognostic and therapeutic implications. Cell Mol Life Sci 2007;64: 3233-47.
22. Rischin D, Fisher R, Peters L, Corry J, Hicks R. Hypoxia in head and neck cancer: studies with hypoxic positron emission tomography imaging and hypoxic cytotoxins. Int J Radiat Oncol Biol Phys 2007;69[Suppl]:S61-3.
23. Rundqvist H, Johnson RS. Hypoxia and metastasis in breast cancer. Curr Top Microbiol Immunol 2010;345:121-39.
24. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638-48.
25. Koch CJ, Kruuv J, Frey HE. Variation in radiation response of mammalian cells as a function of oxygen tension. Radiat Res 1973;53:33-42.
26. Zeng L, Ou G, Itasaka S, Harada H, Xie X, Shibuya K, et al. TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Sci 2008;99:2327-35.
27. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59:3374-8. (Pubitemid 29334495)
28. Moeller BJ, Dreher MR, Rabbani ZN, Schroeder T, Cao Y, Li CY, et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 2005;8:99-110. (Pubitemid 41132739)
29. Schwartz DL, Powis G, Thitai-Kumar A, He Y, Bankson J, Williams R, et al. The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther 2009;8:947-58.
30. Williams KJ, Telfer BA, Brave S, Kendrew J, Whittaker L, Stratford IJ, et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin Cancer Res 2004;10: 8587-93. (Pubitemid 40053426)
31. Dutta PR, Maity A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett 2007;254:165-77. (Pubitemid 47161103)
32. Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 2005;11:795-805. (Pubitemid 40116908)
33. Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005;65:3328-35. (Pubitemid 40524617)
34. Camidge DR, Dziadziuszko R, Hirsch FR. The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers. Clin Lung Cancer 2009;10:262-72.
35. Cosaceanu D, Carapancea M, Castro J, Ekedahl J, Kanter L, Lewensohn R, et al. Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation. Cancer Lett 2005;222:173-81. (Pubitemid 40603644)
36. Gupta AK, Soto DE, Feldman MD, Goldsmith JD, Mick R, Hahn SM, et al. Signaling pathways in NSCLC as a predictor of outcome and response to therapy. Lung 2004;182:151-62. (Pubitemid 38982213)
37. Lee SH, Kim HS, Park WS, Kim SY, Lee KY, Kim SH, et al. Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study. APMIS 2002;110:587-92.
38. Kim IA, Bae SS, Fernandes A, Wu J, Muschel RJ, McKenna WG, et al. Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res 2005;65:7902-10. (Pubitemid 41297268)
39. Konstantinidou G, Bey EA, Rabellino A, Schuster K, Maira MS, Gazdar AF, et al. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res 2009;69:7644-52.
40. Gupta AK, Cerniglia GJ, Mick R, McKenna WG, Muschel RJ. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res 2005;65:8256-65. (Pubitemid 41330590)
41. Jiang Z, Pore N, Cerniglia GJ, Mick R, Georgescu MM, Bernhard EJ, et al. Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. Cancer Res 2007;67:4467-73. (Pubitemid 46815097)
42. Kimple RJ, Vaseva AV, Cox AD, Baerman KM, Calvo BF, Tepper JE, et al. Radiosensitization of epidermal growth factor receptor/HER2- positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status. Clin Cancer Res 2010;16:912-23.
43. Rengan R, Mick R, Pryma D, Lin L, Maity A, Gupta A, et al. A Phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy (CT-RT) for stage IIIA/IIIB NSCLC: a report of toxicities and metabolic response. Int J Radiat Oncol 2009;75:S111.
44. Rengan R, Cengel KA, Hahn SM. Clinical target promiscuity: lessons from ras molecular trials. Cancer Metastasis Rev 2008;27:403-14.
45. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62. (Pubitemid 40093472)
46. Said N, Socha MJ, Olearczyk JJ, Elmarakby AA, Imig JD, Motamed K. Normalization of the ovarian cancer microenvironment by SPARC. Mol Cancer Res 2007;5:1015-30. (Pubitemid 350070757)
47. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007;13:3942-50. (Pubitemid 47037602)
48. Jain RK, Finn AV, Kolodgie FD, Gold HK, Virmani R. Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization. Nat Clin Pract Cardiovasc Med 2007;4:491-502. (Pubitemid 47316647)
49. Nanjundan M, Zhang F, Schmandt R, Smith-McCune K, Mills GB. Identification of a novel splice variant of AML1b in ovarian cancer patients conferring loss of wild-type tumor suppressive functions. Oncogene 2007;26:2574-84. (Pubitemid 46632011)
50. Ng QS, Goh V, Fichte H, Klotz E, Fernie P, Saunders MI, et al. Lung cancer perfusion at multi-detector row CT: reproducibility of whole tumor quantitative measurements. Radiology 2006;239:547-53.
51. Li Y, Yang ZG, Chen TW, Chen HJ, Sun JY, Lu YR. Peripheral lung carcinoma: correlation of angiogenesis and first-pass perfusion parameters of 64-detector row CT. Lung Cancer 2008;61:44-53. (Pubitemid 351862323)
52. Thomassin-Naggara I, Daraï E, Nassar-Slaba J, Cortez A, Marsault C, Bazot M. Value of dynamic enhanced magnetic resonance imaging for distinguishing between ovarian fibroma and subserous uterine leiomyoma. J Comput Assist Tomogr 2007;31:236-42. (Pubitemid 46573362)
53. Yamamoto Y, Nishiyama Y, Kimura N, Ishikawa S, Okuda M, Bandoh S, et al. Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2008;35:236-45.
54. Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005;46:253-60. (Pubitemid 43073432)
55. Cherk MH, Foo SS, Poon AM, Knight SR, Murone C, Papenfuss AT, et al. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET. J Nucl Med 2006;47:1921-6. (Pubitemid 47544979)
56. Koch CJ, Scheuermann JS, Divgi C, Judy KD, Kachur AV, Freifelder R, et al. Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nucl Med Mol Imaging 2010;37:2048-59.
57. Kong FM, Frey KA, Quint LE, Ten Haken RK, Hayman JA, Kessler M, et al. A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol 2007;25:3116-23. (Pubitemid 47218060)
58. Chang JY, Zhang X, Wang X, Kang Y, Riley B, Bilton S, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006;65:1087-96.
59. Gomez DR, Tucker SL, Martel MK, Zhuang Y, Balter PA, Lopez JL, et al. Predictive dosimetric factors for high-grade esophagitis in patients treated for non-small cell lung cancer (NSCLC) with definitive 3D conformal therapy (3D-CRT), intensity modulated radiation therapy (IMRT), or proton beam therapy (PBT). Int J Radiat Oncol 2010;78:S202.
60. Ekberg L, Holmberg O, Wittgren L, Bjelkengren G, Landberg T. What margins should be added to the clinical target volume in radiotherapy treatment planning for lung cancer? Radiother Oncol 1998;48:71-7.
61. Ross CS, Hussey DH, Pennington EC, Stanford W, Doornbos JF. Analysis of movement of intrathoracic neoplasms using ultrafast computerized tomography. Int J Radiat Oncol Biol Phys 1990;18:671-7. (Pubitemid 20129647)
62. Stevens CW, Munden RF, Forster KM, Kelly JF, Liao Z, Starkschall G, et al. Respiratory-driven lung tumor motion is independent of tumor size, tumor location, and pulmonary function. Int J Radiat Oncol Biol Phys 2001;51:62-8. (Pubitemid 32758862)
63. Leter EM, Cademartiri F, Levendag PC, Flohr T, Stam H, Nowak PJ. Four-dimensional multislice computed tomography for determination of respiratory lung tumor motion in conformal radiotherapy. Int J Radiat Oncol Biol Phys 2005;62:888-92. (Pubitemid 40779783)
64. Mageras GS, Yorke E, Rosenzweig K, Braban L, Keatley E, Ford E, et al. Fluoroscopic evaluation of diaphragmatic motion reduction with a respiratory gated radiotherapy system. J Appl Clin Med Phys 2001;2:191-200.
65. Wong JW, Sharpe MB, Jaffray DA, Kini VR, Robertson JM, Stromberg JS, et al. The use of active breathing control (ABC) to reduce margin for breathing motion. Int J Radiat Oncol Biol Phys 1999;44:911-9. (Pubitemid 29284142)
66. Wilson EM, Williams FJ, Lyn BE, Wong JW, Aird EG. Validation of active breathing control in patients with non-small-cell lung cancer to be treated with CHARTWEL. Int J Radiat Oncol Biol Phys 2003;57:864-74. (Pubitemid 37194315)
67. Hanley J, Debois MM, Mah D, Mageras GS, Raben A, Rosenzweig K, et al. Deep inspiration breath-hold technique for lung tumors: the potential value of target immobilization and reduced lung density in dose escalation. Int J Radiat Oncol Biol Phys 1999;45:603-11. (Pubitemid 29462639)
68. Hugo GLJ, Kestin L. Evaluation of 4D image-guided planning and treatment techniques for lung cancer: Potential of daily onlien correction[Abstract]. Int J Radiat Oncol 2005;63:2.
69. Harsolia A, Hugo GD, Kestin LL, Grills IS, Yan D. Dosimetric advantages of four-dimensional adaptive image-guided radiotherapy for lung tumors using online cone-beam computed tomography. Int J Radiat Oncol Biol Phys 2008;70:582-9.
70. Koukourakis MI, Bahlitzanakis N, Froudarakis M, Giatromanolaki A, Georgoulias V, Koumiotaki S, et al. Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma. Br J Cancer 1999;80:1792-6. (Pubitemid 29389634)
71. Choy H, Curran WJ, Scoot CB. Preliminary report of locally advanced multimodality protocol (LAMP): ACR 427: A randomized phase II study of three chemo-radiation regimens with paclitaxel, carboplatin, and thoracic radiation for patients with locally advanced non small cell lung cancer. Proc Am Soc Clin Oncol 2002;291a:1160.
72. Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004;46:87-98. (Pubitemid 39201387)
73. Albain KS, Crowley JJ, Turrisi AT 3rd, Gandara DR, Farrar WB, Clark JI, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 2002;20:3454-60.
74. van Putten JW, Price A, van der Leest AH, Gregor A, Little FA, Groen HJA. A Phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer. Clin Cancer Res 2003;9:2472-7. (Pubitemid 36842086)
75. Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara PN Jr, et al. Southwest Oncology Group. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003;21:2004-10. (Pubitemid 46606390)
76. Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, et al. Hoosier Oncology GroupUS Oncology. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III nonsmall- cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008;26:5755-60.
77. Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S, et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 2010;28:3739-45.
78. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51.
79. Shewach DS, Lawrence TS. Antimetabolite radiosensitizers. J Clin Oncol 2007;25:4043-50. (Pubitemid 47492948)
80. Lehmann LJ, Werner A, Dinter DJ, Mauermann E, Seidling R, Brade J, et al. Scintigraphic evaluation of rhBMP-2-biocoated implants reveals no ectopic bone formation. Biomed Pharmacother 2011; 65:63-8.
81. Brade A, Bezjak A, MacRae R, Laurie S, Sun A, Cho J, et al. Phase I trial of radiation with concurrent and consolidation pemetrexed and cisplatin in patients with unresectable stage IIIA/B non-smallcell lung cancer. Int J Radiat Oncol Biol Phys 2011;79:1395-401.
82. Schild SE, Stella PJ, Geyer SM, Bonner JA, Marks RS, McGinnis WL, et al. Phase III trial comparing chemotherapy plus once-daily or twicedaily radiotherapy in Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002;54:370-8. (Pubitemid 35286800)
83. Olsen C, Paulus R, Komaki R, Varella-Garcia M, Dziadziuszko R, Curran WJ, et al. RTOG 0324: A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients with stage IIIA/B non-small cell lung cancer (NSCLC)-Association between EGFR gene copy number and patients' outcome. J Clin Oncol 2008;26:7607.
84. Choong NW, Mauer AM, Haraf DJ, Lester E, Hoffman PC, Kozloff M, et al. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol 2008;3:1003-11.
85. Dowlati A. Ongoing trials with bevacizumab and other antiangiogenic agents in lung cancer. Clin Lung Cancer 2008;9:S71-5.